Role of Tenascin-C in the differential diagnosis of small round blue cell tumors

Giriş: Bu çalışma; küçük yuvarlak mavi hücreli tümörlerde, serum tenascin-C düzeylerinin teşhis, tedavi ve takiplerdeki yerinin değerlendirilmesi amacıyla planlanmıştır. Gereç ve yöntem: Bu prospektif çalışmaya; 40 hasta ve kontrol grubu olarak 30 sağlıklı çocuk alındı. Hastalardan; tanı anında, tedavinin 3. ve 6. aylarında ve tedavi bittikten sonraki 3. ayda toplam dört defa, kontrol grubundan ise; bir defa serum örneği alınarak tenascin-C düzeyleri ölçüldü. Bulgular: Tüm hasta grubunun her dört ölçüm değeri de kontrol grubuna göre anlamlı derecede yüksekti (sırasıyla; p=0,013, p=0,009, p=0,011 ve p=0,015). Tüm hasta grubu alt gruplarına ayrılarak karşılaştırıldığında ise; sadece Wilms tümörü grubunun, ilk ölçüm değeri, kontrol grubuna göre anlamlı derecede yüksekti (p=0,026). Sonuç: Daha geniş hasta gruplarının katılımıyla yapılacak çalışmalara ihtiyaç olmakla beraber tenascin-C, Wilms tümörü grubunda olduğu gibi, bazı spesifik tümörlerin ayırıcı tanısında yol gösterici olabilir

Küçük yuvarlak mavi hücreli tümörlerin ayırıcı tanısında Tenascin-C'nin rolü

Objective: The aim of this study was to evaluate the significance of serum tenascin-C levels in the diagnosis, treatment, and monitoring of small round blue cell tumors. Materials and methods: Forty patients and 30 healthy children (control group) were included in this prospective study. Serum tenascin-C levels were measured from blood drawn at the time of diagnosis, at the 3rd and 6th months of treatment, and at 3 months following the completion of treatment. While serum tenascin-C levels were measured a total of 4 times in the patient group, they were measured just once in the control group. Results: Each of the four measured serum tenascin-C levels in the patient group was significantly higher than that of the control group (p=0,013, p=0,009, p=0,011 and p=0,015, respectively). However, when the patient group was categorized into subgroups, only those with Wilms tumor had a significantly higher serum tenascin-C level at the time of diagnosis than did the control group (p=0,026). Conclusion: While larger, more thorough studies are needed, our data suggest that tenascin-C may be useful in the differential diagnosis of certain specific tumors, such as the Wilms tumor

___

  • Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease. Philadelphia, Elsevier Inc 2010;474-81.
  • Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol. 2003;200(4):488-99.
  • Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, Stupp R, et al. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Int J Cancer. 2008;122(11):2454-61.
  • Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, et al. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res. 2005;25(1B):489-95.
  • Udalova IA, Ruhmann M, Thomson SJ, Midwood KS. Expression and immune function of tenascin-C. Crit Rev Immunol. 2011;31(2):115-45.
  • Niebroj-Dobosz I. Tenascin-C in human cardiac pathology. Clin Chim Acta. 2012;413(19-20):1516-8.
  • Lebensztejn DM, Sobaniec-Lotowska ME, Kaczmarski M, Voelker M, Schuppan D. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol. 2006;12(21):3338-43.
  • Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789-99.
  • Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4(11):839-49.
  • Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392-401.
  • Ruiz C, Huang W, Hegi ME, Lange K, Hamou MF, Fluri E, et al. Growth promoting signaling by tenascin-C. Cancer Res. 2004;64(20):7377-85.
  • Orend G. Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol. 2005;37(5):1066- 83.
  • Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244(2):143-63.
  • Burchardt ER, Hein R, Bosserhoff AK. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin Exp Dermatol. 2003;28(5):515-20.
  • Pauli C, Stieber P, Schmitt UM, Andratschke M, Hoffmann K, Wollenberg B. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck. Anticancer Res. 2002;22(5):3093-7.
  • Pilch H, Schäffer U, Schlenger K, Lautz A, Tanner B, Höckel M, et al. Expression of tenascin in human cervical cancer- association of tenascin expression with clinicopathological parameters. Gynecol Oncol. 1999;73(3):415-21.
  • Iskaros BF, Tanaka KE, Hu X, Kadish AS, Steinberg JJ. Morphologic pattern of tenascin as a diagnostic biomarker in colon cancer. J Surg Oncol. 1997;64(2):98-101.
  • Shoji T, Kamiya T, Tsubura A, Hamada Y, Hatano T, Hioki K, et al. Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res. 1993;55(3):295-7.
  • Riedl S, Bodenmüller H, Hinz U, Holle R, Möller P, Schlag P, et al. Significance of tenascin serum level as tumor marker in primary colorectal carcinoma. Int J Cancer. 1995;64(1):65-9.
  • Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17(7):867-74.